Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 647

1.

Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.

Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E.

Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):709-15.

2.

Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women.

Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Brown DR, Elbasha EH, Paavonen J, Haupt RM; FUTURE I Investigators.

Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1585-94. doi: 10.1158/1055-9965.EPI-09-1235.

3.

Spectrum of genital human papillomavirus infection in a female adolescent population.

Jamison JH, Kaplan DW, Hamman R, Eagar R, Beach R, Douglas JM Jr.

Sex Transm Dis. 1995 Jul-Aug;22(4):236-43.

PMID:
7482107
4.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

5.

Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial.

Six L, Leodolter S, Sings HL, Barr E, Haupt R, Joura EA.

Wien Klin Wochenschr. 2008;120(21-22):666-71. doi: 10.1007/s00508-008-1093-3.

PMID:
19116707
6.

Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women.

Trottier H, Mahmud SM, Lindsay L, Jenkins D, Quint W, Wieting SL, Schuind A, Franco EL; GSK HPV-001 Vaccine Study Group.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):854-62. doi: 10.1158/1055-9965.EPI-08-1012. Epub 2009 Feb 17.

7.

Epidemiological data of different human papillomavirus genotypes in cervical specimens of HIV-1-infected women without history of cervical pathology.

Videla S, Darwich L, Cañadas MP, Paredes R, Tarrats A, Castella E, Llatjos M, Bofill M, Clotet B, Sirera G; HIV-HPV Study Group.

J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):168-75. doi: 10.1097/QAI.0b013e3181938e63.

PMID:
19131892
8.

Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial.

Konno R, Tamura S, Dobbelaere K, Yoshikawa H.

Int J Gynecol Cancer. 2010 Apr;20(3):404-10. doi: 10.1111/IGC.0b013e3181d373a5.

PMID:
20375805
9.

Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination.

Trottier H, Mahmud S, Prado JC, Sobrinho JS, Costa MC, Rohan TE, Villa LL, Franco EL.

J Infect Dis. 2008 May 15;197(10):1436-47. doi: 10.1086/587698.

10.

A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.

Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM.

Cancer Prev Res (Phila). 2009 Oct;2(10):868-78. doi: 10.1158/1940-6207.CAPR-09-0031. Epub 2009 Sep 29.

11.

Incidence and predictors of human papillomavirus-6, -11, -16, and -18 infection in young norwegian women.

Kim S, Arduino JM, Roberts CC, Marsico M, Liaw KL, Skjeldestad FE.

Sex Transm Dis. 2011 Jul;38(7):587-97. doi: 10.1097/OLQ.0b013e31820a9324.

PMID:
21301390
12.

Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study.

Konno R, Tamura S, Dobbelaere K, Yoshikawa H.

Cancer Sci. 2011 Apr;102(4):877-82. doi: 10.1111/j.1349-7006.2011.01878.x. Epub 2011 Feb 17.

13.

Natural history of cervicovaginal papillomavirus infection in young women.

Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD.

N Engl J Med. 1998 Feb 12;338(7):423-8.

14.

A controlled trial of a human papillomavirus type 16 vaccine.

Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU; Proof of Principle Study Investigators.

N Engl J Med. 2002 Nov 21;347(21):1645-51.

15.

Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.

Paavonen J; Future II Study Group.

Curr Med Res Opin. 2008 Jun;24(6):1623-34. doi: 10.1185/03007990802068151. Epub 2008 Apr 23.

PMID:
18435868
16.

Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study.

Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, Abrahamsen M, Inserra P, Olvera S, Hatch K.

J Infect Dis. 2002 Aug 15;186(4):462-9. Epub 2002 Aug 2.

17.

Prevalence and incidence of HPV genital infection in women.

Velicer C, Zhu X, Vuocolo S, Liaw KL, Saah A.

Sex Transm Dis. 2009 Nov;36(11):696-703. doi: 10.1097/OLQ.0b013e3181ad25ff.

PMID:
19652630
18.

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.

Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23. doi: 10.1016/j.ygyno.2009.09.021. Epub 2009 Oct 12.

PMID:
19819540
19.

The natural history of type-specific human papillomavirus infections in female university students.

Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, Coutlée F, Franco EL.

Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):485-90.

20.

The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.

Sigurdsson K, Sigvaldason H, Gudmundsdottir T, Sigurdsson R, Briem H.

Acta Obstet Gynecol Scand. 2009;88(1):27-35. doi: 10.1080/00016340802566770.

PMID:
19031282
Items per page

Supplemental Content

Write to the Help Desk